louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06848179: Smartphone-Based Use of Phonocardiography Technique for Estimating Heart Rate and Heart Rate Variability: Performance Study
Official title: Smartphone-Based Use of Phonocardiography Technique for Estimating Heart Rate and Heart Rate Variability: Performance Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Exercise
Keywords: Auscultation
Smartphone
Heart Sounds
Heart Auscultation
Phonocariodgraphy
Lead sponsor: The University of Hong Kong
Sponsor class: OTHER
Collaborators: name: Laboratory of Data Discovery for Health
First posted: 2025-02-26
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 69
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Apparently healthy volunteers aged 18-69 recruited from the general public

Brief summary: This study aims to investigate the use of heart sound recordings, or phonocardiograms, recorded with smartphones' built-in microphones and accessory microphones to estimate heart rate (HR) and heart rate variability (HRV). HR refers to the number of heart beats per minute, while HRV refers to the variation in the intervals between heart beats.

Participants will have their heart sounds (phonocardiograms) recorded before and after exercise, and electrocardiogram (ECG) and photoplethysmogram (PPG) data recorded before, during, and after exercise to induce a wide range of HR.

Researchers will match the phonocardiograms, ECG, and PPG data to create a database for use in future training and testing of algorithms (including artificial intelligence (AI)).


Eligibility criteria: Inclusion Criteria:

* With no tattoos on their body where a smartwatch will be placed

Exclusion Criteria:

* Not ready to undertake physical activity as assessed by the Physical Activity Readiness Questionnaire (PAR-Q) derived from the Canadian Society for Exercise Physiology
* Implanted active medical devices in the torso, such as pacemakers and defibrillators
* Failure to collect baseline heart sound time series from ECG or both smartphone and auscultation pin before exercise

Primary outcomes:
measure: HR estimation
timeFrame: Day 0
measure: HRV estimation
timeFrame: Day 0
Secondary outcomes:
measure: Participants' comfort level for devices used in this study
timeFrame: Day 0
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01857479: A Randomized Controlled Trial of Inhaled Amphotericin B for Maintaining Remission in Allergic Bronchopulmonary Aspergillosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Allergic Bronchopulmonary Aspergillosis
Keywords: ABPA
Lead sponsor: PIMERIndia
Sponsor class: UNKNOWN
First posted: 2013-05-20
Enrollment: 21
Sex: ALL
Minimum age (years): 12
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Inhaled amphotericin, a antifungal drug would decrease Aspergillus colonization and decrease the occurrence of exacerbations of Allergic Bronchopulmonary Aspergillosis (ABPA).


Eligibility criteria: Inclusion Criteria: ABPA in remission defined as follows:

1. Age 12-65 years
2. Diagnosis of ABPA in the Chest Clinic
3. Received glucocorticoids for management of ABPA according to the Chest clinic protocol (0.5 mg/kg/day for 4 weeks, 0.25 mg/kg/day for 4 weeks, 0.125 mg/kg/day for 4 weeks, subsequently taper and stop steroids over the next 4 weeks).
4. Clinicoradiologic improvement with decline in IgE levels. The chest radiograph and IgE levels after four months of steroid therapy would serve as the baseline

Exclusion Criteria:

1. Failure to provide informed consent
2. Pregnancy
3. Involved in any other research protocol

Primary outcomes:
measure: Time to first relapse
timeFrame: 12 months
Secondary outcomes:
measure: ACQ-7 scores between the two groups
timeFrame: 2, 4, 6, and 12 months
measure: Number of asthma exacerbations requiring oral steroids
timeFrame: 12 months
measure: Improvement in forced expiratory volume in the first second (FEV1)
timeFrame: 2, 4, 6, and 12 months
measure: Adverse effects of therapy in both the arms
timeFrame: 12 months
Other outcomes:
Locations:
city: Chandigarh
country: India
facility: Chest Clinic, PGIMER
Study officials:
References:
Clinical trial NCT06519279: Freezing of Gait - Clinical Outcomes Assessment
Official title: An International Multimodal Protocol for Assessing Freezing of Gait in Individuals Living with Parkinson's Disease
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: PD - Parkinson's Disease
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
Collaborators: name: KU Leuven
name: Oregon Health and Science University
name: University of Sydney
name: Radbound University Medical Center
name: University of Waterloo
name: Emory University
name: University of Rochester
First posted: 2024-07-25
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: FOG \& NON-DOG

Brief summary: To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).


Eligibility criteria: Inclusion Criteria:

1. Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines;
2. Able to walk independently for a distance of 10 meters, without walking aid;
3. Absence of a Deep Brain Stimulator;
4. Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study.
5. For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).

Exclusion Criteria:

1. Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class \>3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait.
2. Unwilling to temporarily delay the morning anti-Parkinsonian medication.
3. Preganacy and

Primary outcomes:
measure: Validate the newly-developed ClinRO
timeFrame: 12/2025
Secondary outcomes:
measure: Asses the importance of the FOG symptom for patients
timeFrame: 12/2025
Other outcomes:
Locations:
city: Tel aviv
country: Israel
facility: Tel Aviv Saurasky Medical Center
Study officials:
References:
Clinical trial NCT04765579: Investigation of the Effect of 4 in 1 Block Application on Postoperative Analgesia in Knee Surgeries.
Official title: Effects of Ultrasonography-guided 4in1 Block Application on Postoperative Analgesia in Patients Undergoing Knee Surgery
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Visual Analogy Scala
Lead sponsor: Derince Training and Research Hospital
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 62
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: knee surgeries performed with spinal anesthesia

Brief summary: to investigate the effects of ultrasonography-guided 4in1 block application on postoperative analgesia in patients undergoing knee surgery. After knee surgeries performed with spinal anesthesia, 4in1 block will be applied in one group and medical analgesics will be applied in the service in the other group.


Eligibility criteria: Inclusion Criteria:

* ASA I-II
* 18-60 ages
* who were informed about the study and accepted,
* who underwent knee surgery

Exclusion Criteria:

* ASA III-IV
* who are under general anesthesia
* who do not agree to participate in the study
* who are urgently operated

Primary outcomes:
measure: visuel analogue scale
timeFrame: 6 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT04492579: Newborns Supplemented With Gentle-UHT Donor Milk
Official title: Neonates Supplemented With Gentle-UHT Donor Human Milk in the First Week of Life
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Newborns
Breast Milk Expression
Lead sponsor: LactaLogics, Inc
Sponsor class: INDUSTRY
Collaborators: name: Renown Regional Medical Center
First posted: 2020-07-30
Enrollment: 31
Sex: ALL
Maximum age (years): 4
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study evaluates the effects of providing breastfeeding mothers with Gentle-UHT donor human milk (GHM) after discharge to bridge the gap during delayed onset lactation, to support an exclusive human milk diet and continued breastfeeding through the infant's first week of life. The investigators aim to determine the safety of GHM, and if GHM provided to breastfeeding mothers of outpatient babies with early weight loss will ensure babies adequately gain weight according to age-matched controls.


Eligibility criteria: Inclusion Criteria:

* Gestational age \>36 weeks
* Exclusively fed human milk
* Age \<96 hours (4 days)

Exclusion Criteria:

* Previous admittance to the neonatal intensive care unit
* Supplementation of any formula

Primary outcomes:
measure: Weight gain
timeFrame: 8-9 days of life
Secondary outcomes:
measure: Exclusive human milk diet
timeFrame: 8-9 days of life
Other outcomes:
Locations:
city: Port Saint Lucie
country: United States
facility: LactaLogics, Inc.
state: Florida
Study officials:
affiliation: Renown Regional Medical Center
name: Rebecca Perry, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01716884: China STEMI-PCI Program
Official title: China STEMI-PCI Program
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: ST Segment Elevation Myocardial Infarction
Keywords: STEMI
reperfution
primary PCI
Lead sponsor: Peking University First Hospital
Sponsor class: OTHER
Collaborators: name: Abbott Medical Devices
name: Sanofi
First posted: 2012-10-30
Enrollment: 4000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: STEMI Patients enrolled and followed up 1 year

Brief summary: 1. Registration
2. Performing in three stages
3. Major aim: Much more and standard reperfusion therapy in STEMI patients


Eligibility criteria: Inclusion Criteria:

* Onset of STEMI within 12h
* Onset of STEMI within 12-36h needing primary PCI

Exclusion Criteria:

-

Primary outcomes:
measure: The reperfusion ratio
timeFrame: up to 1 day
Secondary outcomes:
measure: Door to Balloon time
timeFrame: up to 1 day
measure: BMS ratio
timeFrame: up to 1 day
measure: health economic evaluation
timeFrame: up to 1 year
Other outcomes:
Locations:
city: Beijing
country: China
facility: Division of Cardiology, Peking University First Hospital
Study officials:
References:
Clinical trial NCT06886984: Effects of Social Media on Oral Hygiene With Orthodontic Patients
Official title: EFFECTS OF SOCIAL MEDIA REMINDERS ON ORAL HYGIENE MOTIVATION WITH FIXED ORTHODONTIC TREATMENT
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Periodontal Inflammation
Orthodontic Appliance Complication
Keywords: oral hygiene
social media
fixed orthodontic treatment
Lead sponsor: Karadeniz Technical University
Sponsor class: OTHER
First posted: 2025-03-20
Enrollment: 44
Sex: ALL
Minimum age (years): 14
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study was to compare the efficacy of traditional and social media motivation strategies in improving oral hygiene with fixed orthodontic treatment.

Detailed description: In this prospective, controlled clinical trial, 44 orthodontic patients were equally allocated to a social media (Facebook, Instagram and X (Twitter)) and control group. The control group received only traditional communication including verbal and written instructions at the beginning of the therapy. The patients assigned to social media group received two posts twice a week reminding hygiene procedures in addition to standardized oral hygiene instructions. Periodontal scores were obtained at 4-6-week intervals during six appointments (T1-T6) using the gingival index (GI), bleeding index (BI), and planimetric plaque quantification (PI) on photographs

Eligibility criteria: Inclusion Criteria:

* Class 1 malocclusion who had simple or moderate crowding and did not require tooth extraction.

Exclusion Criteria:

* Patients with functional appliances; surgical patients; those with a history of periodontitis, poor orthodontic hygiene, and/or physical or mental disabilities were excluded from the study.

Primary outcomes:
measure: Gingival Index
timeFrame: 6 months ( a score for every month)
Secondary outcomes:
measure: Bleeding Index
timeFrame: 6 months ( a score for every month)
measure: Plaque Index
timeFrame: 6 months ( a score for every month)
Other outcomes:
Locations:
city: Trabzon
country: Turkey
facility: Karadeniz Technical University, Faculty of Dentistry
Study officials:
affiliation: Karadeniz Technical University
name: Barıs BASER, Assoc. Prof
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00451984: Hepatitis Vaccination in HIV Infection: Role of Adjuvant Interleukin-2
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: HIV Infections
Hepatitis A
Hepatitis B
Keywords: interleukin-2
vaccination
treatment experienced
Lead sponsor: Aalborg University Hospital
Sponsor class: OTHER
First posted: 2007-03-26
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The response to vaccination for hepatitis is reduced in patients with HIV infection. The hypothesis of the study is that adjuvant interleukin-2 administered subcutaneously at the time of vaccination improves the response rate.


Eligibility criteria: Inclusion Criteria:

* Adults with stable antiretroviral therapy and negative for hepatitis A or B

Exclusion Criteria:

* Prior hepatitis A or B

Primary outcomes:
measure: Antibody response to hepatitis A and hepatitis B
Secondary outcomes:
Other outcomes:
Locations:
city: Aalborg
country: Denmark
facility: Department of Infectious Diseases, Aalborg Hospital
city: Aarhus
country: Denmark
facility: Department of Infectious Diseases, Skejby Hospital
Study officials:
affiliation: Aalborg Hospital, DK-9000 Aalborg, Denmark
name: Henrik Nielsen, MD, DMSci
role: STUDY_CHAIR
References:
Clinical trial NCT02093884: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department
Official title: Texting 2 Initiate: A Pilot Study Using Text Messaging to Communicate With Adolescent Females in the Pediatric Emergency Department (T2I)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pregnancy
Keywords: Pregnancy
Pregnancy, unplanned
Reproductive behavior
Pregnancy in Adolescence
Text messaging
Lead sponsor: Columbia University
Sponsor class: OTHER
Collaborators: name: Society of Family Planning
First posted: 2014-03-21
Enrollment: 100
Sex: FEMALE
Minimum age (years): 14
Maximum age (years): 19
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The objective of this study is to develop and test an emergency department (ED)-based intervention which uses text messages to facilitate contraception initiation.

Detailed description: Our hypothesis is that adolescent females at high pregnancy risk who receive text message reminders and motivational messages that promote contraception and referral to the Family Planning Clinic are more likely to start effective contraception than those who receive standard paper-based referral to the Family Planning Clinic alone.

Eligibility criteria: Inclusion Criteria:

* Aged 14-19 years
* Sexually active with males in the past three months
* Presenting to the ED for a reproductive health complaint.

Exclusion Criteria:

* Presently pregnant
* Too ill for participation per the attending physician
* Cognitively impaired
* In foster care or a ward of the state
* Does not speak English or Spanish
* Does not own a cellular or mobile phone with text messaging capabilities
* Used contraception at last intercourse and/or is currently using any "highly effective" or "effective" form of contraception (as defined by the World Health Organization)
* Does not live in Manhattan or the Bronx

Primary outcomes:
measure: Initiation of highly effective contraception, as defined by the World Health Organization.
timeFrame: 3 months after initial enrollment
Secondary outcomes:
measure: Patient visits to Family Planning Clinic
timeFrame: 3 months after initial enrollment
measure: Follow up for contraceptive counseling to a doctor or nurse
timeFrame: 3 months after initial enrollment
measure: Change in pregnancy intentions
timeFrame: 3 months after initial enrollment
Other outcomes:
measure: Text messaging intervention safety
timeFrame: 3 months after initial enrollment
Locations:
city: Manhattan
country: United States
facility: Morgan Stanley Children's Hospital Emergency Department
state: New York
Study officials:
affiliation: Columbia University
name: Lauren Chernick, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fonhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8(8):CD013680. doi: 10.1002/14651858.CD013680.
Clinical trial NCT00819884: To Evaluate 24-hr Glucose After OD vs BD AZD1656
Official title: A Randomised, Two Way Cross-Over, Single-Blind, Phase I Study to Evaluate 24-hr Glucose Profiles in Patients With T2DM When Dosed OD and BD on Top of Metformin for Four Days With AZD1656
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Type II Diabetes
Keywords: Type II Diabetes
24 hour glucose profile
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-01-09
Enrollment: 36
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the 24-hour glucose profiles in diabetic patients treated with metformin following once daily and twice daily oral dosing


Eligibility criteria: Inclusion Criteria:

* type II diabetes patients, female with non child-bearing potential
* Type 2 Diabetes Mellitus (T2DM) diagnosis confirmed by C-peptide \>0.3nmol/L and no Glutamic acid decarboxylase (GAD) antibodies at enrolment (screening)
* Treatment with metformin as single therapy for T2DM for at least 30 days prior to enrolment and the metformin dose must have been unchanged during this period

Exclusion Criteria:

* History of ischemic heart disease, symptomatic heart failure, stroke, transitory ischemic attack or symptomatic peripheral vascular disease
* Any clinically significant abnormality identified on physical examination, laboratory test or ECG, which in the judgement of investigator would compromise the subject's safety or successful participation in the clinical study

Primary outcomes:
measure: 24-hr glucose (Calculated plasma glucose AUC0-24, change in fasting plasma glucose)
timeFrame: Repeated sampling during the 24 hour period on day -1, 4 and 8
Secondary outcomes:
measure: Safety and tolerability (Adverse events (AEs) during the study, blood pressure (BP), pulse rate, safety laboratory variables (incl. glucose) and investigator's interpretation of electrocardiogram (ECG)
timeFrame: Frequent measurements during the study period
measure: Pharmacokinetic variables (Area under the plasma conc vs. time curve (AUC0-24), maximum plasma conc (Cmax), time to reach maximum plasma conc(tmax), terminal elimination half-life and apparent oral clearance
timeFrame: Repeated sampling at pre-specified timepoints on day 4 and 8
measure: Pharmacodynamics (S-Insulin AUC0-24 and C-peptide AUC0-24)
timeFrame: Repeated sampling during the 24 hour period on day -1, 4 and 8
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Research Site
state: Texas
Study officials:
affiliation: AstraZeneca R&D Mölndal
name: Klas Malmberg, MD, PhD, Prof.,
role: STUDY_DIRECTOR
affiliation: Healthcare Discoveries LLC Icon Development Solutions
name: Emanuel P DeNoia, M.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06000384: Is Ultrasound Comparable to Chest X-ray in Verification of Intensive Care Patients Enteral Feeding Tube Positioning.
Official title: Investigate if Ultrasound is Comparable to Chest X-ray in Verification of Intensive Care Patients Enteral Feeding Tube Positioning in an Observational Study
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Intensive Care Patient
Keywords: Intensive care patient
Enteral feeding tube
Lead sponsor: Norwegian University of Science and Technology
Sponsor class: OTHER
First posted: 2023-08-21
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Intensive care patients in need of enteral tube feeding

Brief summary: The goal of this observational study is to investigate methodological if ultrasound is comparable to chest X-ray in verification of intensive care patients enteral feeding tube positioning.

The main question to answer is: Is ultrasound a comparable method to chest X-ray in verification of intensive care patients enteral feeding tube positioning.

Detailed description: In Norway, around 4000 patients are yearly in need of ventilator, and many of them will need enteral nutrition through a feeding tube. 40 % of all intensive care patients have signs of malnutrition. If ultrasound is a comparable method to chest X-ray in verification of intensive care patients enteral feeding tube positioning, then enteral nutrition in many cases can be started several hours earlier than using chest X-ray verification. The ultrasound examination will be performed in a research based in a 4-step approach. In this project 20-30 intensive care patients prescribed by a medical physician to have an enteral feeding tube will be included in the project due to written informed consent by 1) Awake intensive care patient or by 2) Patients informal caregiver if the patient is not competent to consent.

Eligibility criteria: Inclusion Criteria:

* Intensive care patient prescribed by a medical physician to have an enteral feeding tube

Exclusion Criteria:

* \<18 years

Primary outcomes:
measure: Measuring enteral tube position both by standard chest X-ray and ultrasound
timeFrame: maximum five minutes for each method
Secondary outcomes:
Other outcomes:
Locations:
city: Lillehammer
country: Norway
facility: Lillehammer sykehus, Sykehuset Innlandet
state: Innlandet
Study officials:
affiliation: Norwegian University of Science and Technology - NTNU.
name: Irene Lie, Professor
role: PRINCIPAL_INVESTIGATOR
References: